| Drug / Therapy | A Phase 3 Study of NTLA-2001 in ATTRv-PN |
| Indication | — |
| Decision Type | Phase 3 |
| Trial Phase | Phase 3 |
| ClinicalTrials.gov | NCT06672237 |
Intellia Therapeutics (NTLA) operates in the Gene Editing sector. The current BTS Score is 61 (Grade: C).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The Phase 3 date for A Phase 3 Study of NTLA-2001 in ATTRv-PN by Intellia Therapeutics (NTLA) is scheduled for July 1, 2027. This is the target date for the FDA to make a decision on this application.
A Phase 3 Study of NTLA-2001 in ATTRv-PN is being developed by Intellia Therapeutics for the treatment of its target indication. It is currently in Phase 3 clinical trials.
If A Phase 3 Study of NTLA-2001 in ATTRv-PN receives FDA approval, Intellia Therapeutics (NTLA) would be able to market the drug in the United States for its target indication. This typically leads to significant stock price movement for biotech companies. Investors should monitor the Phase 3 date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for NTLA on DilutionWatch at dilutionwatch.com/stock/NTLA.html.
You can view the full BiotechSign company profile for Intellia Therapeutics (NTLA) at biotechsign.com/app/company/NTLA, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSign is not a registered investment advisor.